2023. Targeting toll-like receptor 4 (TLR4) and the NLRP3 inflammasome: Novel and emerging therapeutic targets for hyperuricaemia nephropathy. Biomolecules and Biomedicine. (Dec. 2023), 688–697. DOI:https://doi.org/10.17305/bb.2023.9838.